Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Aurinia Pharmaceuticals (AUPH) Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis

November 1, 2021 10:12 AM EDT

- Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021

- Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compared with placebo -

- Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with stable eGFR at 30 months -

VICTORIA, British Columbia--(BUSINESS... More